Rockwell Medical
Rockwell Medical's revenue fell 31.8% to $69 million in fiscal 2025. Its operating margin was −6.8%, down from 0.6% a year earlier. Free cash flow was −$1 million, against $3 million a year earlier. The diluted share count rose 15.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Rockwell Medical lost money in fiscal 2025: a net loss of $5 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 22 | 22 | 11 | 22 | 25 |
| Debt incl. finance leases | 24 | 12 | 10 | 10 | 10 |
| Net debt (negative means net cash) | 1 | −10 | −0 | −12 | −15 |
| Net debt to EBITDA | — | — | — | −4.2x | — |
| Debt to equity | 9.3x | 0.8x | 0.5x | 0.3x | 0.3x |
| Interest coverage | −12.8x | −8.7x | −2.9x | 0.5x | −4.2x |
| Current ratio | 1.7x | 2.0x | 1.7x | 2.6x | 4.0x |
| Quick ratio | 1.5x | 1.7x | 1.4x | 2.2x | 3.6x |
Cash flow
Projections
Project Rockwell Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Rockwell Medical shares on the open market, and 2 insiders sold $3,153, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | Heather HunterChief Operating Officer | Sold plan | 2,868 | $0.84 | $2,409 | Form 4 |
| Jan 2, 2026 | Jesse NeriSVP and CFO | Sold plan | 886 | $0.84 | $744 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 7 of 9 | 3 of 9 |
| Rule of 40 | 3.2% | 24.5% | −33.5% |
| Altman Z'' | −23.43 | −18.00 | −18.33 |
| Accruals ratio | 2.0% | −8.4% | −8.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 4 of 9 | 7 of 9 | 3 of 9 |
Compare
Put Rockwell Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Rockwell Medical | FY25 | −31.8% | −6.8% | −1.7% | −17.4% | — | 3 | |
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | Compare |
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | Compare |
| Spero Therapeutics | FY25 | 39.2% | 9.4% | — | — | — | — | Compare |
| Assembly Biosciences | FY25 | 153.5% | −16.8% | −56.9% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 53 | 57 | 63 | 61 | 62 | 62 | 73 | 84 | 102 | 69 |
| Revenue growth | −3.7% | 7.5% | 10.6% | −3.3% | 1.5% | −0.4% | 17.6% | 14.8% | 21.4% | −31.8% |
| Gross profit | 7 | 4 | −2 | 3 | 3 | −2 | 4 | 9 | 18 | 12 |
| Research and development | 6 | 6 | 6 | 7 | 7 | 7 | 3 | 1 | 0 | 0 |
| Operating income | −20 | −26 | −32 | −34 | −28 | −30 | −17 | −7 | 1 | −5 |
| Net income | −20 | −26 | −32 | −34 | −31 | −33 | −19 | −8 | −0 | −5 |
| Diluted EPS (US$) | −0.39 | −0.51 | −0.61 | −0.56 | −0.41 | −3.83 | −1.31 | −0.37 | −0.03 | −0.15 |
| Diluted shares (millions) | 51 | 51 | 53 | 61 | 76 | 8 | 14 | 23 | 31 | 36 |
| Cash flow | ||||||||||
| Cash from operations | −12 | −21 | −20 | −27 | −30 | −34 | −17 | −9 | 4 | −1 |
| Capital expenditure | — | — | — | — | — | — | — | 0 | 1 | 0 |
| Free cash flow | — | — | — | — | — | — | — | −10 | 3 | −1 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 10 | 7 | 4 | 5 | 0 | 1 | 0 | 1 | 1 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 17 | 8 | 34 | 26 | 59 | 22 | 22 | 11 | 22 | 25 |
| Debt incl. finance leases | — | — | — | 0 | 22 | 24 | 12 | 10 | 10 | 10 |
| Total assets | 83 | 59 | 53 | 44 | 78 | 49 | 47 | 52 | 59 | 57 |
| Total liabilities | 30 | 26 | 25 | 24 | 44 | 46 | 32 | 31 | 27 | 20 |
| Shareholders' equity | 53 | 33 | 27 | 20 | 34 | 2 | 14 | 21 | 33 | 37 |
| Margins and ratios | ||||||||||
| Gross margin | 12.7% | 6.5% | −2.5% | 4.6% | 4.4% | −3.9% | 5.6% | 10.4% | 17.2% | 16.9% |
| Operating margin | −37.9% | −45.2% | −51.2% | −56.3% | −45.7% | −49.0% | −23.1% | −8.0% | 0.6% | −6.8% |
| Net margin | −37.2% | −45.2% | −50.7% | −55.7% | −49.7% | −52.8% | −25.6% | −10.1% | −0.5% | −7.7% |
| Free cash flow margin | — | — | — | — | — | — | — | −11.6% | 3.1% | −1.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | 3.2% | 24.5% | −33.5% |
| Return on capital | — | — | — | — | — | — | — | −41.9% | 2.3% | −17.4% |
| Return on equity | −34.4% | −60.4% | −106.8% | −143.4% | −113.4% | −178.0% | −224.5% | −47.7% | −1.8% | −15.3% |
| Return on assets | −23.2% | −36.5% | −57.7% | −70.5% | −50.6% | −51.7% | −39.2% | −17.1% | −0.9% | −9.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | −4.2x | — |